Safety and Cost-Effectiveness of Bridge Therapies for Invasive Dental Procedures in Patients with Mechanical Heart Valves.
10.3349/ymj.2014.55.4.937
- Author:
Ki Bum WON
1
;
Seung Hyun LEE
;
Hyuk Jae CHANG
;
Chi Young SHIM
;
Gue Ru HONG
;
Jong Won HA
;
Namsik CHUNG
Author Information
1. Department of Cardiology, St. Luke's International Hospital, Tokyo, Japan.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Anticoagulation;
bridge therapy;
dental procedure;
low molecular weight heparin;
mechanical heart valve
- MeSH:
Aged;
Anticoagulants/*therapeutic use;
Dentistry, Operative/*methods;
Enoxaparin/therapeutic use;
Female;
*Heart Valve Prosthesis;
Heparin, Low-Molecular-Weight/*therapeutic use;
Humans;
Male;
Middle Aged
- From:Yonsei Medical Journal
2014;55(4):937-943
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Bridge anticoagulation therapy is mostly utilized in patients with mechanical heart valves (MHV) receiving warfarin therapy during invasive dental procedures because of the risk of excessive bleeding related to highly vascular supporting dental structures. Bridge therapy using low molecular weight heparin may be an attractive option for invasive dental procedures; however, its safety and cost-effectiveness compared with unfractionated heparin (UFH) is uncertain. MATERIALS AND METHODS: This study investigated the safety and cost-effectiveness of enoxaparin in comparison to UFH for bridge therapy in 165 consecutive patients (57+/-11 years, 35% men) with MHV who underwent invasive dental procedures. RESULTS: This study included 75 patients treated with UFH-based bridge therapy (45%) and 90 patients treated with enoxaparin-based bridge therapy (55%). The bleeding risk of dental procedures and the incidence of clinical adverse outcomes were not significantly different between the UFH group and the enoxaparin group. However, total medical costs were significantly lower in the enoxaparin group than in the UFH group (p<0.001). After multivariate adjustment, old age (> or =65 years) was significantly associated with an increased risk of total bleeding independent of bridging methods (odds ratio, 2.51; 95% confidence interval, 1.15-5.48; p=0.022). Enoxaparin-based bridge therapy (beta=-0.694, p<0.001) and major bleeding (beta=0.296, p=0.045) were significantly associated with the medical costs within 30 days after dental procedures. CONCLUSION: Considering the benefit of enoxaparin in cost-effectiveness, enoxaparin may be more efficient than UFH for bridge therapy in patients with MHV who required invasive dental procedures.
